Immucell vs Myriad Genetics: revenue, profit, margins and growth compared
Immucell brought in $27.6M of revenue in fiscal 2025, Myriad Genetics $824.5M in fiscal 2025. Revenue changed by +4.3% at Immucell and -1.6% at Myriad Genetics on the year before, so Immucell grew faster. Immucell kept -3.8% of its revenue as net profit, Myriad Genetics -44.4%.
Fiscal years as each company reports them; the two may end in different months.
Questions about Immucell and Myriad Genetics
Which is bigger by revenue, Immucell or Myriad Genetics?
Myriad Genetics is bigger by revenue: $824.5M in fiscal 2025, against $27.6M for Immucell in fiscal 2025.
Which keeps more of its revenue as profit, Immucell or Myriad Genetics?
Immucell had a net margin of -3.8% in fiscal 2025; Myriad Genetics had -44.4% in fiscal 2025.
Which grew revenue faster, Immucell or Myriad Genetics?
In their latest fiscal years revenue changed by +4.3% at Immucell and -1.6% at Myriad Genetics.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.